Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy
复制标题
DOI：
10.1067/s0002-9378(03)00629-x
复制
发表时间：
2003-11-01
影响因子：
9.8
通讯作者：
Berman, ML
中科院分区：
文献类型：
--
作者：
Loizzi, V;Chan, JK;Berman, ML
目的：本研究的目的是确定复发性卵巢癌患者在极端耐药检测指导治疗后的预后。研究设计：将50名根据极端耐药试验指导进行化疗的妇女与50名经经验治疗的平衡良好的对照组进行比较。结果：在铂敏感组中，极端耐药定向治疗患者的总有效率为65%，而经验治疗患者的总有效率为35% （P = 0.02）。极端耐药试验组的总中位生存期为38个月，无进展中位生存期为15个月，对照组为21个月，无进展中位生存期为7个月（P = 0.005，总中位生存期；P = 0.002，无进展中位生存期）。在铂耐药组中，接受检测指导治疗的患者没有改善的结果。在多变量分析中，铂敏感疾病、极端耐药指导治疗和疾病早期是提高生存率的独立预测因素。结论：在这项回顾性分析中，我们的研究结果表明，患有铂敏感疾病并接受极端耐药定向化疗的复发性卵巢癌患者的预后得到改善。需要随机、前瞻性、对照试验。
OBJECTIVE: The purpose of this study was to determine the outcome of patients with recurrent ovarian carcinoma after extreme drug resistance assay-directed therapy.STUDY DESIGN: Fifty women who were treated with chemotherapy based on extreme drug resistance assay guidance were compared with 50 well-balanced control subjects who were treated empirically.RESULTS: In the platinum-sensitive group, patients with extreme drug resistance-directed therapy had an overall response rate of 65% compared with 35% in the patients who were treated empirically (P = .02). The overall and progression-free median survival were 38 and 15 months in the extreme drug resistance assay group compared with 21 and 7 months in the control group, respectively (P = .005, overall; P = .0002, progression free). In the platinum-resistant group, there was no improved outcome in the patients who underwent assay-guided therapy. In multivariate analysis, platinum-sensitive disease, extreme drug resistance-guided therapy and early stage of disease were independent predictors for improved survival.CONCLUSION : In this retrospective analysis, our results indicate an improved outcome in patients with recurrent ovarian carcinoma who have platinum sensitive disease and who underwent extreme drug resistance-directed chemotherapy. Randomized, prospective, controlled trials are needed.